Mary Weitzel, CEO, President and Co-Founder has an engineering degree and MBA plus 30 years of senior management experience in specialty polymers, chemicals, women’s personal care and OTC drug products, four years as President of Instead Inc., and a total 18 years in women’s reproductive health.
We at Yaso Therapeutics are developing a vaginal gel, called Yaso-GEL, that uses a single proprietary drug to prevent pregnancy as well as genital herpes, gonorrhea, and chlamydia. The gel is mucoadhesive, non-irritating, relatively low-cost, and stable. Yaso-GEL aims to be an MPT that can fill the need for non-hormonal contraceptives and protect women from sexually transmitted infections (STIs).
This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.